BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
FXYD4
,
Coagulation
,
Leukemia
,
Hypothalamus
,
Metabolism of nitric oxide
,
Fenofibrate
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
2 2'- difluorodeoxyuridine
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for 2 2'- difluorodeoxyuridine
Explore Curated Studies Results
Literature
Most Relevant Literature
Effect of its deaminated metabolite, 2',2'-difluorodeoxyuridine, on the transport and toxicity of ge…
The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitab…
New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine.
Retention studies of 2'-2'-difluorodeoxycytidine and 2'-2'-difluorodeoxyuridine nucleosides and nucl…
Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Sol…
Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participant…
A Study for Participants With Pancreatic Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ